Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma

References

• Grange JM. Effective vaccination against tuberculosis-a new ray of hope. Clin Exp Immunol 2000; 120:232 - 4; http://dx.doi.org/10.1046/j.1365-2249.2000.01145.x; PMID: 10792369
   PubMed Web of Science ®Google Scholar
• Maraveyas A, Baban B, Kennard D, Rook GA, Westby M, Grange JM, et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 1999; 10:817 - 24; http://dx.doi.org/10.1023/A:1008307821189; PMID: 10470429
   PubMed Web of Science ®Google Scholar
• Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998; 82:568 - 73; http://dx.doi.org/10.1046/j.1464-410X.1998.00803.x; PMID: 9806190
   PubMedGoogle Scholar
• Nicholson SGK, Guile K, John J, Clarke IA, Diffley J, Donnellan P, et al. A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res 2003; 13:389 - 93; http://dx.doi.org/10.1097/00008390-200308000-00008; PMID: 12883365
   PubMed Web of Science ®Google Scholar
• Assersohn L, Souberbielle BE, O’Brien ME, Archer CD, Mendes R, Bass R, et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin Oncol (R Coll Radiol) 2002; 14:23 - 7; http://dx.doi.org/10.1053/clon.2001.0030; PMID: 11899903
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Saini A, Smith IE, Webb A, Gregory K, Mendes R, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000; 83:853 - 7; http://dx.doi.org/10.1054/bjoc.2000.1401; PMID: 10970684
   PubMed Web of Science ®Google Scholar
• Dalgleish AG. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 2011; 29:8501 - 5; http://dx.doi.org/10.1016/j.vaccine.2011.09.012; PMID: 21933695
   PubMed Web of Science ®Google Scholar
• Stanford JL, Stanford CA, O’Brien ME, Grange JM. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 2008; 44:224 - 7; http://dx.doi.org/10.1016/j.ejca.2007.08.021; PMID: 17928219
   PubMed Web of Science ®Google Scholar
• Patel PM, Sim S, O’Donnell DO, Protheroe A, Beirne D, Stanley A, et al. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur J Cancer 2008; 44:216 - 23; http://dx.doi.org/10.1016/j.ejca.2007.11.003; PMID: 18164612
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199 - 206; http://dx.doi.org/10.1200/JCO.2009.23.4799; PMID: 19917835
   PubMed Web of Science ®Google Scholar
• Fowler D, Liu WM, Smith P, Dalgleish AG. Supernatant from tumour cells treated with chemotherapy stimulate professional antigen presenting cells in vitro. Ejc Suppl 2009; 7:115 - 6
   Web of Science ®Google Scholar
• Lahey T, Arbeit RD, Bakari M, Horsburgh CR, Matee M, Waddell R, et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine 2010; 28:7652 - 8; http://dx.doi.org/10.1016/j.vaccine.2010.09.041; PMID: 20875492
   PubMed Web of Science ®Google Scholar
• Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 2000; 82:1009 - 12; http://dx.doi.org/10.1054/bjoc.1999.1034; PMID: 10737381
   PubMed Web of Science ®Google Scholar
• Evans C, Morrison I, Heriot AG, Bartlett JB, Finlayson C, Dalgleish AG, et al. The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer 2006; 94:1412 - 9; http://dx.doi.org/10.1038/sj.bjc.6603104; PMID: 16641913
   PubMed Web of Science ®Google Scholar
• Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol 2002; 9:762 - 70; http://dx.doi.org/10.1007/BF02574498; PMID: 12374659
   PubMed Web of Science ®Google Scholar
• Morton DLMN, Thompson JF, Kelley MC, Faries M, Wagner J, Schneebaum S, et al, MMAIT Clinical Trials Group. An International, ranodmized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007; 25:8508
   Web of Science ®Google Scholar
• Sanki A, Scolyer RA, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol 2009; 35:313 - 9; http://dx.doi.org/10.1016/j.ejso.2008.04.011; PMID: 18590949
   PubMed Web of Science ®Google Scholar
• Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 2011; 104:111 - 5; http://dx.doi.org/10.1002/jso.21903; PMID: 21381040
   PubMed Web of Science ®Google Scholar
• Ollila DW, Gleisner AL, Hsueh EC. Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. J Surg Oncol 2011; 104:420 - 4; http://dx.doi.org/10.1002/jso.21961; PMID: 21858837
   PubMed Web of Science ®Google Scholar
• Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, et al. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Ann Oncol 2012; 23:1314 - 9; http://dx.doi.org/10.1093/annonc/mdr363; PMID: 21930686
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517 - 26; http://dx.doi.org/10.1056/NEJMoa1104621; PMID: 21639810
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507 - 16; http://dx.doi.org/10.1056/NEJMoa1103782; PMID: 21639808
   PubMed Web of Science ®Google Scholar